Hogan Lovells advised pSivida Corp. on its acquisition of Icon Bioscience, Inc. as part of its rebranding initiative into EyePoint Pharmaceuticals, Inc. pSivida, which officially became…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
